EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan

Akihiko Shimomura, Yasuaki Sagara, Ryo Koto, Masakazu Fujiwara, Yuka Kanemura, Hiroshi Kitagawa, Shigehira Saji

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01572-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer, 2024. Verfasst von Akihiko Shimomura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Anthracyclines, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anthracycline- and taxane-based chemotherapy regimens are established treatments for human epidermal growth factor receptor (HER)2-negative early-stage breast cancer with high risk of recurrence. This study examined the prevalence of these chemotherapy regimens as perioperative therapy, the patterns of retreatment, and factors influencing prescription choices in Japan.

Methods

This observational cohort study focused on high-risk early-stage breast cancer patients not undergoing anti-HER2 therapy, utilizing data from a hospital-based claims database in Japan spanning from April 2008 to September 2021.

Results

Of 42,636 high-risk patients who underwent breast cancer surgery, 32,133 (75.4%) were categorized as having luminal-type (received endocrine therapy) and 10,503 (24.6%) as having triple-negative cancer (not receiving any endocrine therapies). Most patients (98.7%) with luminal-type breast cancer received perioperative therapy, and 40.3% of those received anthracycline/taxane. In the triple-negative group, 57.0% of all patients received perioperative therapy and of those, 93.4% received anthracycline/taxane. Being over 40 years old, having an early stage (clinical stage ≤ II), and receiving treatment in non-specialized facilities were associated with less use of anthracycline/taxane in the luminal-type group. For the triple-negative group, associated factors with less use of anthracycline/taxane included being over 60 years old, treatment in small hospital (capacity < 200 beds), and treatment in non-specialized facilities.

Conclusions

Approximately half the patients in both the luminal-type and triple-negative groups were prescribed anthracycline and/or taxane for perioperative chemotherapy. The choice was associated with patient age, cancer stage, and the scale and specialization of the treatment facilities. This study sheds light on the current state of breast cancer treatment practices in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthracyclinesErb-b2 Receptor Tyrosine KinasesTaxoidsBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleJapanMiddle AgedAdultAgedBridged-Ring CompoundsNeoplasm StagingTriple Negative Breast NeoplasmsChemotherapy, Adjuvant

Stichwörter der Autor:innen

AnthracyclineEarly-stage breast cancerLuminal-typeTaxaneTriple-negative

Substanzen

AnthracyclinesErb-b2 Receptor Tyrosine KinasesTaxoidsBridged-Ring CompoundsERBB2 protein, humantaxane

Autor:innen und Institutionen

  • Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan.
  • Medical Department, AstraZeneca K.K., Osaka, Japan.
  • Department of Medical Oncology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, Fukushima, 960-1295, Japan. ss-saji@wa2.so-net.ne.jp.

Förderung

  • AstraZeneca

Zitieren

APA

Shimomura, A., Sagara, Y., Koto, R., Fujiwara, M., Kanemura, Y., Kitagawa, H., & Saji, S. (2024). Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan. Breast Cancer. https://doi.org/10.1007/s12282-024-01572-8

Vancouver

Shimomura A, Sagara Y, Koto R, Fujiwara M, Kanemura Y, Kitagawa H, et al. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan. Breast Cancer. 2024. doi:10.1007/s12282-024-01572-8

BibTeX
@article{Shimomura2024,
  author = {Shimomura, Akihiko and Sagara, Yasuaki and Koto, Ryo and Fujiwara, Masakazu and Kanemura, Yuka and Kitagawa, Hiroshi and Saji, Shigehira},
  title = {Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01572-8}
}
Kostenlos starten →